VIDEO: Sitravatinib plus nivolumab does not offer OS benefit over docetaxel in NSCLC subset

Press/Media

Period	Nov 14 2023

Media coverage

Title	VIDEO: Sitravatinib plus nivolumab does not offer OS benefit over docetaxel in NSCLC subset
Media name/outlet	Healio
Country/Territory	United States
Date	11/14/23
URL	https://www.healio.com/news/hematology-oncology/20231114/video-sitravatinib-plus-nivolumab-does-not-offer-os-benefit-over-docetaxel-in-nsclc-subset
Persons	Hossein Borghaei